Clinical Trials in Overt Diabetic Nephropathy

  • Staffan Björck

Abstract

There is only limited data showing if and how the kidney benefits from antihypertensive treatment in non-diabetic renal disease. In contrast to this, several studies have shown that aggressive antihypertensive treatment is probably the most important factor to determine the rate of decline in kidney function in diabetic nephropathy. The evidence that antihypertensive treatment can preserve renal function is based on the much reduced rate of renal disease progression after effective blood pressure control [1, 2]. These studies compare the rate of decline in glomerular filtration rate during intervention with retrospective data. This is not ideal since uncontrolled factors might influence the outcome. However, the effect of antihypertensive treatment is so profound that it is obviously very important for the kidney in diabetic nephropathy. Anyone that treats these patients observe that end-stage renal failure is postponed by antihypertensive treatment and that the disease runs an accelerated course during uncontrolled hypertension.

Keywords

Glomerular Filtration Rate Diabetic Nephropathy Antihypertensive Treatment Antiproteinuric Effect Renal Disease Progression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mogensen CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982; 285: 685–688.PubMedCrossRefGoogle Scholar
  2. 2.
    Parving H-H, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA. Effect of antihypertensive treatment on kidney function in diabetic nephropathy. BMJ 1987; 294: 1443–1447.PubMedCrossRefGoogle Scholar
  3. 3.
    Björck S, Nyberg G, Mulec H, Granerus G, Herlitz H, Aurell M. Beneficial effects of angiotensin converting enzyme inhibition on renal function in patients with diabetic nephropathy. BMJ 1986; 293: 467–470.CrossRefGoogle Scholar
  4. 4.
    Taguma Y , Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y. Effect of Captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 1985; 313: 1617–1620.PubMedCrossRefGoogle Scholar
  5. 5.
    Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 (insulin-dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 1990; 33: 470–476.PubMedCrossRefGoogle Scholar
  6. 6.
    Elving LD, Wetzeis JFM, de Nobel E, Hoitsma AJ, Berden JHM. Captopril acutely lowers albuminuria in normotensive patients with diabetic nephropathy. Am J Kidney Dis 1992; 20: 559–563.PubMedGoogle Scholar
  7. 7.
    Bakris GL, Barnhill BW, Sadler R. Treatment of arterial hypertension in diabetic humans: importance of therapeutic selection, Kidney Int 1992; 41: 912–919.PubMedCrossRefGoogle Scholar
  8. 8.
    Holdaas H, Hartmann A, Lien MG, Nilsen L, Jervell J, Fachald P, Endresen L, Djøseland O, Berg KJ. Contrasting effects of lisinopril and nifidepine on albuminuria and tubular transport functions in insulin dependent diabetics with nephropathy. J Intern Med 1991; 229: 163–170.PubMedCrossRefGoogle Scholar
  9. 9.
    Mimran A, Insua A, Ribstein J, Bringer J, Monnier L. Comparative effect of Captopril and Nifedipine in normotensive patients with incipient diabetic nephropathy. Diabetes Care 1988; 11: 850–853.PubMedCrossRefGoogle Scholar
  10. 10.
    Gansevoort RT, Apperloo AJ, Heeg JE, De Jong PE, De Zeeuw D. The antiproteinuric effect of antihypertensive agents in diabetic nephropathy. Arch Intern Med 1992; 152: 2137–2138.PubMedCrossRefGoogle Scholar
  11. 11.
    Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–343.PubMedCrossRefGoogle Scholar
  12. 12.
    Stornello M, Valvo EV, Scapellato L. Comparative effects of enalapril, atenolol and chlorothalidone on blood pressure and kidney function of diabetic patients affected by arterial hypertension and persistent proteinuria. Nephron 1991; 58: 52–57.PubMedCrossRefGoogle Scholar
  13. 13.
    Kasiske BL, Kalil RSN, Ma JZ, Liao M, Keane WF. Effect of antihypertensive therapy on the kidney in patients with diabetes: A meta-regression analysis. Ann Intern Med 1993; 118: 129–138.PubMedCrossRefGoogle Scholar
  14. 14.
    Mulec H, Johnsen S-A, Björck S. Long-term enalapril treatment in diabetic nephropathy. Kidney Int 1994; in press.Google Scholar
  15. 15.
    Parving H-H, Hommel E, Smidt UM. Protection of kidney function and decrease in albuminuria by Captopril in insulin dependent diabetics with nephropathy. BMJ 1988; 297: 1086–1091.PubMedCrossRefGoogle Scholar
  16. 16.
    Ferder L Daccordi H, Panzalis M, Inserra F. Angiotensin converting enzyme inhibitors versus calcium antagonists in the treatment of diabetic hypertensive patients. Hypertension 1992; 19: suppl. 2: 11–237-II-242.CrossRefGoogle Scholar
  17. 17.
    Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–581.PubMedCrossRefGoogle Scholar
  18. 18.
    Lewis EJ, Hunsickler LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.PubMedCrossRefGoogle Scholar
  19. 19.
    Heeg JE, De Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272–279.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Staffan Björck

There are no affiliations available

Personalised recommendations